Clinical Trial Search block Test
An Interventional, Efficacy, And Safety, Phase 3 Randomized, Double-Blind, Placebo-Controlled Study With An Open-Label Extension To Investigate Rimegepant In Migraine Prevention In Adolescents Greater Than Or Equal To 12 And Less Than 18 Years Of Age With Chronic Migraine
Rimegepant Chronic Migraine
What is the goal of the study?
This is a global, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of rimegepant in migraine prevention in adolescents ? 12 to < 18 years of age with chronic migraine. All participants are to be administered 75 mg (1 x 75 mg ODT) rimegepant or matching placebo.
Who can participate in the study?
Everyone